Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Irena Hrusovsky"'
Autor:
A. von Rohr, Jerome Voegeli, Berthold Emmerich, Robert Olie, Christian Taverna, Irena Hrusovsky, Harold Pliskat, Georg Hess, Claas Frohn
Publikováno v:
Oncology. 79(3-4)
Objectives: This multicenter, retrospective survey evaluated the efficacy and safety of bortezomib retreatment in patients with relapsed multiple myeloma who had responded to initial bortezomib treatment. Methods: Clinical records of 94 patients rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0be7f7eeae28ba36ea9d6598b1ede84
https://pubmed.ncbi.nlm.nih.gov/21372599
https://pubmed.ncbi.nlm.nih.gov/21372599
Autor:
Christian Taverna, Jerome Voegeli, Irena Hrusovsky, Berthold Emmerich, Claas Frohn, Albert von Rohr, Robert Olie, Georg Hess, Harold Pliskat, Monika Engelhardt
Publikováno v:
Blood. 112:2775-2775
In myeloma therapy retreatment after successful therapy is frequently considered. Here we present pooled data from a German and Swiss multicenter, retrospective survey (26866138MMY4014). The survey started in Germany and was later extended to Switzer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ece01803a21f85279a345a83c1b0689b
https://doi.org/10.1182/blood.v112.11.2775.2775
https://doi.org/10.1182/blood.v112.11.2775.2775
Publikováno v:
Blood. 110:4851-4851
Bortezomib(Bo) was approved for therapy of relapsed Multiple Myeloma (MM) in 2003-for use in Germany 2004. There is growing evidence that combination of Bo with conventional chemotharapy agents could improve MM patients’ (pts) outcome(P.Richardson
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f892ade8208fdc0dd84cc0ba7d6c071
https://doi.org/10.1182/blood.v110.11.4851.4851
https://doi.org/10.1182/blood.v110.11.4851.4851
Publikováno v:
Blood. 106:5122-5122
Bortezomib has been approved for recurrent or therapy-resistent multiple myeloma in 2003. There is growing evidence that combination therapy of bortezomib with other agents considerably improves results (Richardson P, ASH 2004). Bendamustine is an al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::865971882ed4bea8ca4cc6c5778cb1ee
https://doi.org/10.1182/blood.v106.11.5122.5122
https://doi.org/10.1182/blood.v106.11.5122.5122
Autor:
Hrusovsky, I., Emmerich, B., von Rohr, A., Voegeli, J., Taverna, C., Olie, R.A., Pliskat, H., Frohn, C., Hess, G.
Publikováno v:
Oncology; 2011, Vol. 79 Issue 3/4, p247-254, 8p